Cargando…

Efficacy and Treatment-Related Adverse Events of Romidepsin in PTCL Clinical Studies: A Systematic Review and Meta-Analysis

Background: Peripheral T-cell lymphoma (PTCL) is an extensive class of biologically and clinically heterogeneous diseases with dismal outcomes. The histone deacetylase inhibitor (HDACi) romidepsin was approved for relapsed and refractory (R/R-PTCL) in 2011. This meta-analysis was performed to assess...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Jun, Han, Xinle, Lin, Suwen, Qiu, Chen, Zhu, Lijun, Huang, Zoufang, Hou, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602095/ https://www.ncbi.nlm.nih.gov/pubmed/34805202 http://dx.doi.org/10.3389/fmed.2021.732727

Ejemplares similares

Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis
por: Du, Jun, et al.
Publicado: (2021)

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
por: Lu, Guang, et al.
Publicado: (2023)

Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study
por: Chiappella, Annalisa, et al.
Publicado: (2023)

Editorial: PTCL from genes to therapy
por: Janikova, Andrea
Publicado: (2022)

Romidepsin-induced neutrophilic urticaria
por: Scott, Brian, et al.
Publicado: (2016)

Improving Reporter Gene Assay Methodology for Evaluating the Ability of Compounds to Restore P53 Activity
por: Han, Xinle, et al.
Publicado: (2022)

Romidepsin in the treatment of cutaneous T-cell lymphoma
por: Jain, Salvia, et al.
Publicado: (2011)

Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
por: Barbarotta, Lisa, et al.
Publicado: (2015)

Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin
por: Cruickshank, M N, et al.
Publicado: (2017)

PTCL, NOS: An update on classification, risk-stratification, and treatment
por: Weiss, Jonathan, et al.
Publicado: (2023)

Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques
por: Kleinman, Adam J., et al.
Publicado: (2020)

Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors
por: Nettersheim, Daniel, et al.
Publicado: (2018)

Burrowing through the Heterogeneity: Review of Mouse Models of PTCL-NOS
por: Cutucache, Christine E., et al.
Publicado: (2016)

Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
por: Foss, Francine, et al.
Publicado: (2014)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Mitochondria-specific peptide amphiphiles induce mitochondrial dysfunction and peripheral T-cell lymphomas (PTCL) damage
por: Sun, Qi, et al.
Publicado: (2022)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
por: Meng, Long, et al.
Publicado: (2021)

How molecular advances may improve the diagnosis and management of PTCL patients
por: Drieux, Fanny, et al.
Publicado: (2023)

Crosstalk among the proteome, lysine phosphorylation, and acetylation in romidepsin-treated colon cancer cells
por: Wang, Tian-Yun, et al.
Publicado: (2016)

Incidence of adverse events in paediatric procedural sedation in the emergency department: a systematic review and meta-analysis
por: Bellolio, M Fernanda, et al.
Publicado: (2016)

Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Lee, Jane J., et al.
Publicado: (2021)

Serum copper levels and risk of major adverse cardiovascular events: a systematic review and meta-analysis
por: Muñoz-Bravo, Carlos, et al.
Publicado: (2023)

Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non–small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Yu, Xiaolin, et al.
Publicado: (2021)

Romidepsin targets multiple survival signaling pathways in malignant T cells
por: Valdez, B C, et al.
Publicado: (2015)

Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma
por: Irlé, Claudius, et al.
Publicado: (2016)

Synergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction
por: Habibi, Hussain, et al.
Publicado: (2019)

Immunosuppression-associated primary cutaneous plasmablastic lymphoma secondary to romidepsin
por: Costello, Collin M., et al.
Publicado: (2019)

Simvastatin-romidepsin combination kills bladder cancer cells synergistically
por: Okubo, Kazuki, et al.
Publicado: (2021)

Early long-term low-dosage colchicine and major adverse cardiovascular events in patients with acute myocardial infarction: a systematic review and meta-analysis
por: Zhou, Yifang, et al.
Publicado: (2023)

Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis
por: Li, Sicong, et al.
Publicado: (2022)

Efficacy of N-acetylcysteine in Preventing Acute Kidney Injury and Major Adverse Cardiac Events After Cardiac Surgery: A Meta-Analysis and Trial Sequential Analysis
por: Zhao, Jingtao, et al.
Publicado: (2022)

Lymphoma Microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification
por: Miyawaki, Kohta, et al.
Publicado: (2022)

Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
por: Sager, Philip T, et al.
Publicado: (2015)

Use of class I histone deacetylase inhibitor romidepsin in combination regimens
por: Petrich, Adam, et al.
Publicado: (2016)

Romidepsin Controls Chronic Lymphocytic Leukemia in a Patient with Mycosis Fungoides
por: Lemchak, David. M., et al.
Publicado: (2016)

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
por: Conforti, Franco, et al.
Publicado: (2017)

Is Partially Thrombosed False Lumen Really a Predictor for Adverse Events in Uncomplicated Type B Aortic Dissection: A Systematic Review and Meta-Analysis?
por: Wu, Jinlin, et al.
Publicado: (2022)

Predicting major adverse cardiovascular events for secondary prevention: protocol for a systematic review and meta-analysis of risk prediction models
por: Akyea, Ralph K, et al.
Publicado: (2020)

Antithrombotic regimens for the prevention of major adverse cardiac events in chronic coronary syndrome: A systematic review and network meta-analysis
por: Marques, Gustavo Lenci, et al.
Publicado: (2023)

Peripheral T-cell Lymphoma-Unspecified (PTCL-U) Presenting with Hypereosinophilic Syndrome and Pleural Effusions
por: Choi, Won, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_utnfkbv54bbtejq22egv5slfcj